EPIZYME, INC. (NASDAQ:EPZM) Files An 8-K Regulation FD Disclosure

Item7.01

Epizyme, Inc. (the Company) intends to present a company
overviewat the 35th AnnualJ.P. MorganHealthcare Conference on
January9, 2017. The slide deck to be used at suchpresentationis
being furnished as Exhibit 99.1 to this Current Report onForm8-K.

The information responsive to Item7.01 of this Form 8-K,
including Exhibit 99.1, shall not be deemed filed for purposes of
Section18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act) or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.

(d) The following exhibits are included in this report:

About EPIZYME, INC. (NASDAQ:EPZM)

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs. It develops small molecule inhibitors of other chromatin modifying proteins, or CMPs. Its lead product candidate, tazemetostat, is a selective inhibitor of the EZH2 HMT. It is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma, or NHL, and one Phase II study in adults and one Phase I study in children with certain genetically-defined solid tumors. It has programs in development, including a Phase I clinical trial of pinometostat, an inhibitor of the DOT1L HMT, for the treatment of children with MLL-r, an acute leukemia with genetic alterations of the MLL gene.

EPIZYME, INC. (NASDAQ:EPZM) Recent Trading Information

EPIZYME, INC. (NASDAQ:EPZM) closed its last trading session down -0.10 at 12.00 with 505,625 shares trading hands.